We are providing FREE consultations via PHONE or VIDEO conferencing for your safety and convenience. Read More!

A National Securities Arbitration & Investment Fraud Law Firm

Silver Law Group Investigates Aquestive Therapeutics, Inc. (AQST)

Silver Law Group is investigating Aquestive Therapeutics, Inc. (AQST) regarding potential violations of federal securities laws. If you have losses from investing in Aquestive Therapeutics, Inc. (AQST) stock, contact Silver Law Group for consultation at no cost at (800) 975-4345 or by email at ssilver@silverlaw.com. Aquestive Therapeutics, Inc. (AQST) Drug Libervant Aquestive Therapeutics, Inc. (AQST) is a specialty pharmaceutical company based out of New Jersey that “focuses on identifying, developing, and commercializing various products to address unmet medical needs.” On September 25, 2020, Aquestive said that it had received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) for its New Drug Application for Libervant Buccal Film. Libervant is a drug being developed to manage seizure clusters.Silver Law Group is investigating Aquestive Therapeutics, Inc. (AQST) regarding potential violations of federal securities laws.

If you have losses from investing in Aquestive Therapeutics, Inc. (AQST) stock, contact Silver Law Group for consultation at no cost at (800) 975-4345 or by email at ssilver@silverlaw.com.

Aquestive Therapeutics, Inc. (AQST) Drug Libervant

Aquestive Therapeutics, Inc. (AQST) is a specialty pharmaceutical company based out of New Jersey that “focuses on identifying, developing, and commercializing various products to address unmet medical needs.”

On September 25, 2020, Aquestive said that it had received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) for its New Drug Application for Libervant Buccal Film. Libervant is a drug being developed to manage seizure clusters.

Aquestive told investors that in the CRL, the FDA cited a study submitted by the company that showed that certain weight groups had a “lower drug exposure level than desired”. Aquestive said it intended to give information to the FDA on adjusting doses to have the desired exposure levels.

The news caused Aquestive’s stock price to fall almost 35% on September 28, 2020, causing significant investor losses.

Initial Public Offering

Aquestive held its initial public offering (IPO) in July, 2018, raising $67.5 million with 4,500,000 shares. BMO Capital Markets and RBC Capital Markets were joint book-running managers with Wedbush PacGrow and JMP Securities acting as co-lead managers for the offering.

Recovering Aquestive Therapeutics, Inc. (AQST) Investment Losses

If you have investment losses with Aquestive Therapeutics, Inc. (AQST), contact Silver Law Group, a nationally-recognized class action law firm representing investors, to discuss options to recover your losses.

Our securities class action attorneys work with large groups of investors who have been the victim of securities or investment fraud. Many of our cases involve corporate misconduct, Ponzi schemes and other frauds. Our team of lawyers, accountants investigators work with you to help maximize your recovery.

Silver Law Group represents investors who have been the victims of investment fraud. Our attorneys represent investors in class actions against issuers in state or federal court and investors in securities arbitration claims against Wall Street firms for stockbroker misconduct.

Scott Silver, Silver Law Group’s managing partner, is the chairman of the Securities and Financial Fraud Group of the American Association of Justice and represents investors around the country and internationally in securities investment fraud cases. Contact us today at ssilver@silverlaw.com or toll free at (800) 975-4345.

Contact Information